With multiple clinical trials and approval applications in train, nuclear medicine superstar Telix Pharmaceuticals (ASX:TLX) is like one of those irritatingly brilliant all-round students.

VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following ...

Today's crop of last minute quarterly 'homework' isn't hiding too much of the nasty stuff synonomous with 'just-in-time' ...

As global biotech faces increasing pressure to deliver more with less, several ASX-listed healthcare companies are working to ...

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

European pharma companies are breathing a sigh of relief after the Trump administration posed a 15% tariff, rather than 200% ...

In 2025, more adults over 45 are actively searching for natural ways to support their hearing-not just to address the ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...

Hallucinations are a known problem with generative AI models—and Elsa is no different, according to Jeremy Walsh, the head of AI at the FDA. “Elsa is no different from lots of [large language models] ...

Trump over the weekend requested that grand jury transcripts related to United States v. Epstein be unsealed—a seeming sop to his angry supporters that falls far short of the release of all ...